Technical Analysis for SCLP - Scancell Holdings Plc

Grade Last Price % Change Price Change
D 19.75 0.00% 0.00
SCLP closed unchanged on Friday, February 3, 2023, on 34 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Multiple of Ten Bearish Other 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Multiple of Ten Bearish Other 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup -2.23%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Lower Bollinger Band 10 days ago
Up 1% 10 days ago
Rose Above 10 DMA 12 days ago
Up 2% 12 days ago
Possible NR7 12 days ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Scancell Holdings Plc Description

Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Biotechnology Medicine Pipe Clinic Branches Of Biology Cancer Medical Specialties Therapy Clinical Trial Biopharmaceutical Antibody Immunology Therapies Tumor Immune System Antibodies Vaccine Lung Cancer Immunotherapy Monoclonal Antibodies Cancer Therapeutics Treatment Of Cancer

Is SCLP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 29.4
52 Week Low 10.5
Average Volume 1,221,673
200-Day Moving Average 16.28
50-Day Moving Average 23.88
20-Day Moving Average 23.47
10-Day Moving Average 21.55
Average True Range 1.33
RSI 31.51
ADX 32.92
+DI 16.01
-DI 29.07
Chandelier Exit (Long, 3 ATRs) 23.41
Chandelier Exit (Short, 3 ATRs) 22.99
Upper Bollinger Bands 28.34
Lower Bollinger Band 18.59
Percent B (%b) 0.12
BandWidth 41.51
MACD Line -1.15
MACD Signal Line -0.50
MACD Histogram -0.6464
Fundamentals Value
Market Cap 161.01 Million
Num Shares 815 Million
EPS -1.50
Price-to-Earnings (P/E) Ratio -13.17
Price-to-Sales 0.00
Price-to-Book 12.26
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.95
Resistance 3 (R3) 21.00 20.65 20.75
Resistance 2 (R2) 20.65 20.34 20.63 20.68
Resistance 1 (R1) 20.20 20.16 20.15 20.15 20.62
Pivot Point 19.85 19.85 19.83 19.83 19.85
Support 1 (S1) 19.40 19.54 19.35 19.35 18.88
Support 2 (S2) 19.05 19.36 19.03 18.82
Support 3 (S3) 18.60 19.05 18.75
Support 4 (S4) 18.55